Drugs / VGX-1027
VGX-1027
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00760396 | Sep → Nov 2008 | — | VGX Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00627120 | Feb → Sep 2008 | — | VGX Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04590547 | May 2021 → Aug 2022 | COVID-19, pneumonitis | GeneOne Life Science, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGX-1027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00760396 ↗ |
| Known as | GIT 27 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1320667 ↗ |
| Known as | GIT-027 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1320667 ↗ |
| Known as | GLS-1027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04590547 ↗ |
| Known as | Zenuzolac | ChEMBL registry synonym — accepted as the source's own label CHEMBL1320667 ↗ |
| Modality | Small molecule | — CHEMBL1320667 ↗ |
| Route | Oral | “multiple oral doses” NCT00760396 ↗ |